U.S. markets close in 1 hour 42 minutes
  • S&P 500

    4,208.36
    -38.23 (-0.90%)
     
  • Dow 30

    33,984.11
    -315.22 (-0.92%)
     
  • Nasdaq

    13,934.21
    -138.65 (-0.99%)
     
  • Russell 2000

    2,300.95
    -19.12 (-0.82%)
     
  • Crude Oil

    72.01
    -0.11 (-0.15%)
     
  • Gold

    1,847.50
    -8.90 (-0.48%)
     
  • Silver

    27.67
    -0.02 (-0.07%)
     
  • EUR/USD

    1.2047
    -0.0086 (-0.71%)
     
  • 10-Yr Bond

    1.5180
    +0.0190 (+1.27%)
     
  • GBP/USD

    1.4031
    -0.0051 (-0.36%)
     
  • USD/JPY

    110.4050
    +0.3710 (+0.34%)
     
  • BTC-USD

    38,696.39
    -2,556.34 (-6.20%)
     
  • CMC Crypto 200

    958.68
    -33.79 (-3.40%)
     
  • FTSE 100

    7,184.95
    +12.47 (+0.17%)
     
  • Nikkei 225

    29,291.01
    -150.29 (-0.51%)
     

The CASI Pharmaceuticals (NASDAQ:CASI) Share Price Is Up 53% And Shareholders Are Holding On

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.

Some CASI Pharmaceuticals, Inc. (NASDAQ:CASI) shareholders are probably rather concerned to see the share price fall 40% over the last three months. But that doesn't change the fact that the returns over the last three years have been respectable. After all, the stock has performed better than the market (46%) over that time, over which it gained 53%.

View our latest analysis for CASI Pharmaceuticals

Because CASI Pharmaceuticals made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).

earnings-and-revenue-growth
earnings-and-revenue-growth

It's good to see that there was some significant insider buying in the last three months. That's a positive. On the other hand, we think the revenue and earnings trends are much more meaningful measures of the business. If you are thinking of buying or selling CASI Pharmaceuticals stock, you should check out this free report showing analyst profit forecasts.

A Different Perspective

CASI Pharmaceuticals shareholders are down 52% for the year, but the market itself is up 19%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Longer term investors wouldn't be so upset, since they would have made 8.7%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Case in point: We've spotted 3 warning signs for CASI Pharmaceuticals you should be aware of.

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: insiders have been buying them).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.